{"TopicDetails": {"type": 0, "ccm2Id": 42932540, "cftId": 0, "identifier": "EDIDP-CBRN-MCM-2020", "title": "CBRN medical countermeasures, such as preventive and therapeutic immunotherapy", "publicationDateLong": 1584662400000, "callIdentifier": "EDIDP-CBRN-2020", "callTitle": "Chemical Biological Radiological Nuclear (CBRN) detection capabilities and medical countermeasures", "callccm2Id": 42932634, "allowPartnerSearch": true, "workProgrammepart": {"id": 273552, "ccm_id": 31113051, "wp_part": "EDIDP-2019-2020", "wp_year": "EDIDP-2019-2020", "wp_title": "EDIDP-2019-2020", "wp_website": "https://ec.europa.eu/growth/content/2019-calls-proposals-european-defence-industrial-development-programme-edidp_en", "wp_document": "http://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/wp-call/edidp-wp1920_en.pdf"}, "frameworkProgramme": {"id": 31109727, "abbreviation": "EDIDP", "description": "European Defence Industrial Development Programme"}, "programmeDivision": [{"id": 31109729, "abbreviation": "EDIDP-1-1", "description": "EDIDP-1-1"}, {"id": 31109728, "abbreviation": "EDIDP-1", "description": "EDIDP-1"}], "topicMGAs": [], "tags": ["CBRN medical countermeasures, such as preventive and therapeutic immunotherapy"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "EDIDP-AG EDIDP Action grant", "typeOfMGA": []}], "plannedOpeningDate": "15 April 2020", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["01 December 2020"]}], "latestInfos": [{"approvalDate": "Oct 28, 2020 5:12:29 PM", "lastChangeDate": "Oct 28, 2020 5:12:29 PM", "content": "<p>For UK applicants:<br />\r\nPlease be aware that, pursuant to Article 127(7)(b) of the EU-UK Withdrawal Agreement*, the Commission has notified the UK of the application of the derogation based on that article to programmes, procedures and information exchanges in the field of space which grant access to security-related sensitive information**.<br />\r\nAs regards EDIDP, this derogation applies to two topics of the EDIDP-SSAEW-2020 call related to Space Situational Awareness:<br />\r\n-&nbsp;&nbsp; &nbsp;EDIDP-SSAEW-SC2-2020 (Advanced Space Command and Control (SC2) capability to process and exploit SSA data generated from sensors and catalogues to provide a complete space picture); and <br />\r\n-&nbsp;&nbsp; &nbsp;EDIDP-SSAEW-SSAS-2020 (Enhanced SSA sensors for accurate identification and characterization of existing Geostationary Earth Orbit (GEO) and Low Earth Orbit (LEO) public and private assets).<br />\r\nWhat is now the status of the UK regarding EDIDP 2020? <br />\r\nFor all EDIDP 2020 call topics where the above derogation does not apply (all but EDIDP-SSAEW-SC2-2020 and EDIDP-SSAEW-SSAS-2020), the UK will continue to be considered a Member State of the EU. References to undertakings established in a Member State of the EU are to be understood as including undertakings established in the UK.<br />\r\nFor the EDIDP-SSAEW-SC2-2020 and EDIDP-SSAEW-SSAS-2020 call topics, the UK will be considered a third country. References to undertakings established in a Member State of the EU are to be understood as not including undertakings established in the UK.<br />\r\nWhat is now the status of UK entities regarding EDIDP 2020? <br />\r\nFor all EDIDP call topics where the derogation does not apply (all but EDIDP-SSAEW-SC2-2020 and EDIDP-SSAEW-SSAS-2020), entities established in the UK will be able to apply as beneficiaries or subcontractors involved in the action.<br />\r\nFor the EDIDP-SSAEW-SC2-2020 and EDIDP-SSAEW-SSAS-2020 calls:<br />\r\n-&nbsp;&nbsp; &nbsp;Entities established in the UK will not be eligible as beneficiaries, linked third parties nor subcontractors involved in the action. They will only be able to participate as associated partners under Article 7(6) of the EDIDP Regulation (without receiving any funding, provided that, inter alia, security of information and supply are ensured and that the cooperation does not contravene the security and defence interests of the Union and its Member States);<br />\r\n-&nbsp;&nbsp; &nbsp;Entities established in a Member State but controlled by the UK or a by a UK entity will be eligible as beneficiaries, linked third parties or subcontractors involved in the action only if the guarantees required by Article 7(4) of the EDIDP Regulation are provided;<br />\r\n-&nbsp;&nbsp; &nbsp;Entities established in the UK or established in a Member State but controlled by the UK or a by a UK entity will be able to participate in an action as &ldquo;other subcontractors or suppliers&rdquo;. This is without prejudice to the provisions of Article 12(2) of the EDIDP Regulation, which will apply.<br />\r\n<em>* Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community (OJ L 29, 31.1.2020, p. 7).<br />\r\n** Commission Decision of 2 October 2020 on the application of Article 127(7){b) of the Withdrawal Agreement (C(2020)6634 final).</em></p>\r\n<p style=\"margin: 0px; padding: 3px 0px; text-align: left; color: rgb(0, 0, 0); text-transform: none; line-height: 18.9px; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-variant: normal; word-spacing: 0px; white-space: normal; orphans: 2; -webkit-text-stroke-width: 0px; background-color: transparent;\">&nbsp;</p>\r\n<p>&nbsp;</p>"}, {"approvalDate": "Sep 25, 2020 7:22:04 PM", "lastChangeDate": "Sep 25, 2020 7:22:04 PM", "content": "<p><span style=\"text-align: left; color: rgb(0, 0, 0); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12px; font-variant: normal; word-spacing: 0px; display: inline; white-space: normal; orphans: 2; float: none; -webkit-text-stroke-width: 0px; background-color: transparent;\"> </span><span lang=\"EN-IE\" style=\"margin: 0px; color: black; font-family: &quot;Arial&quot;,sans-serif; font-size: 11pt;\"> </span><span lang=\"EN-IE\" style=\"font-size:10.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;color:#001000;mso-ansi-language:EN-IE\">The Guide for Applicants (v2.1), Annex 2 (v2.3) and Annex 8 (v1.2) of the Submission form have been updated.</span></p>\r\n<p><span lang=\"EN-IE\" style=\"font-size:10.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#001000;&#10;mso-ansi-language:EN-IE\">EDIDP related FAQ are now available in the Get Support section.&nbsp;</span></p>\r\n<p style=\"margin: 0px; padding: 3px 0px; text-align: left; color: rgb(0, 0, 0); text-transform: none; line-height: 18.9px; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-variant: normal; word-spacing: 0px; white-space: normal; orphans: 2; -webkit-text-stroke-width: 0px; background-color: transparent;\">&nbsp;</p>\r\n<p>&nbsp;</p>"}, {"approvalDate": "Jul 23, 2020 5:04:55 PM", "lastChangeDate": "Jul 23, 2020 5:04:55 PM", "content": "<p><span style=\"text-align: left; color: rgb(0, 0, 0); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12px; font-variant: normal; word-spacing: 0px; display: inline; white-space: normal; orphans: 2; float: none; -webkit-text-stroke-width: 0px; background-color: transparent;\"> </span></p>\r\n<p><span lang=\"EN-IE\" style=\"margin: 0px; color: black; font-family: &quot;Arial&quot;,sans-serif; font-size: 11pt;\"> </span></p>\r\n<p style=\"margin: 0px; padding: 3px 0px; text-align: left; color: rgb(0, 0, 0); text-transform: none; line-height: 18.9px; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-variant: normal; word-spacing: 0px; white-space: normal; orphans: 2; -webkit-text-stroke-width: 0px; background-color: transparent;\"><span lang=\"EN-US\" style=\"color: rgb(51, 51, 51); font-size: 14px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px;\"><span style=\"display: inline !important; float: none; background-color: transparent; color: rgb(51, 51, 51); font-family: &quot;Arial&quot;,sans-serif; font-size: 14px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\"><span style=\"background-color: transparent; color: rgb(51, 51, 51); display: inline; float: none; font-family: &amp;quot;Arial&amp;quot;,sans-serif; font-size: 14px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\">Eligibility criteria of the Call Texts have been updated.</span></span></span></p>\r\n<p style=\"margin: 0px; padding: 3px 0px; text-align: left; color: rgb(0, 0, 0); text-transform: none; line-height: 18.9px; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-variant: normal; word-spacing: 0px; white-space: normal; orphans: 2; -webkit-text-stroke-width: 0px; background-color: transparent;\"><span lang=\"EN-US\" style=\"color: rgb(51, 51, 51); font-size: 14px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px;\"><span style=\"display: inline !important; float: none; background-color: transparent; color: rgb(51, 51, 51); font-family: &quot;Arial&quot;,sans-serif; font-size: 14px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\">Annex 2 of the Submission Form has been updated.</span></span></p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>"}, {"approvalDate": "Jul 1, 2020 2:20:46 PM", "lastChangeDate": "Jul 1, 2020 2:20:46 PM", "content": "<p><span style=\"text-align: left; color: rgb(0, 0, 0); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12px; font-variant: normal; word-spacing: 0px; display: inline; white-space: normal; orphans: 2; float: none; -webkit-text-stroke-width: 0px; background-color: transparent;\"> </span></p>\r\n<p><span lang=\"EN-IE\" style=\"margin: 0px; color: black; font-family: &quot;Arial&quot;,sans-serif; font-size: 11pt;\"> </span></p>\r\n<p style=\"margin: 0px; padding: 3px 0px; text-align: left; color: rgb(0, 0, 0); text-transform: none; line-height: 18.9px; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-variant: normal; word-spacing: 0px; white-space: normal; orphans: 2; -webkit-text-stroke-width: 0px; background-color: transparent;\"><span lang=\"EN-US\" style=\"color: rgb(51, 51, 51); font-size: 14px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px;\"><span style=\"display: inline !important; float: none; background-color: transparent; color: rgb(51, 51, 51); font-family: &quot;Arial&quot;,sans-serif; font-size: 14px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\">Annex 2 of the Submission Form has been updated.</span></span></p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>"}, {"approvalDate": "Jun 25, 2020 3:16:36 PM", "lastChangeDate": "Jun 25, 2020 3:16:36 PM", "content": "<p><span style=\"text-align: left; color: rgb(0, 0, 0); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12px; font-variant: normal; word-spacing: 0px; display: inline; white-space: normal; orphans: 2; float: none; -webkit-text-stroke-width: 0px; background-color: transparent;\"> </span></p>\r\n<p><span lang=\"EN-IE\" style=\"margin: 0px; color: black; font-family: &quot;Arial&quot;,sans-serif; font-size: 11pt;\">\r\n<p style=\"background-color: transparent; color: rgb(0, 0, 0); font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; line-height: 18.9px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; orphans: 2; padding-bottom: 3px; padding-left: 0px; padding-right: 0px; padding-top: 3px; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\"><span lang=\"EN-US\" style=\"color: rgb(51, 51, 51); font-size: 14px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px;\">Clerical error corrected on the webpage under Topic Conditions:</span></p>\r\n<p><span style=\"display: inline !important; float: none; background-color: transparent; color: rgb(0, 0, 0); font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\"> </span><span style=\"background-color: transparent; color: rgb(0, 0, 0); display: inline; float: none; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\"> </span><span style=\"background-color: transparent; color: rgb(0, 0, 0); display: inline; float: none; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; line-height: 18.9px; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\">&nbsp;4.</span><span style=\"background-color: transparent; color: rgb(0, 0, 0); font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: pre; word-spacing: 0px;\">\t Proposal page limits and layout:</span><span style=\"background-color: transparent; color: rgb(0, 0, 0); display: inline; float: none; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; line-height: 18.9px; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\"> <em><strong>60</strong></em> (Part B - Section 6 &amp; 7)&nbsp;</span></p>\r\n</span></p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>"}, {"approvalDate": "May 29, 2020 1:25:10 PM", "lastChangeDate": "May 29, 2020 1:25:10 PM", "content": "<p><span style=\"text-align: left; color: rgb(0, 0, 0); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12px; font-variant: normal; word-spacing: 0px; display: inline; white-space: normal; orphans: 2; float: none; -webkit-text-stroke-width: 0px; background-color: transparent;\"> </span></p>\r\n<p><span lang=\"EN-IE\" style=\"margin: 0px; color: black; font-family: &quot;Arial&quot;,sans-serif; font-size: 11pt;\">Annex 3 of the Submission form has been updated.</span></p>\r\n<p style=\"margin-top:9.0pt;margin-right:0cm;margin-bottom:9.0pt;margin-left:&#10;0cm;orphans: 2;-webkit-text-stroke-width: 0px;word-spacing:0px\"><span lang=\"EN-IE\" style=\"margin: 0px; color: black; font-family: &quot;Arial&quot;,sans-serif; font-size: 11pt;\">Annex 2 and 4 of the Model Grant Agreement are available now.</span></p>\r\n<p>&nbsp;</p>\r\n<p><span lang=\"EN-US\" style=\"margin: 0px; color: rgb(51, 51, 51); font-family: &quot;Arial&quot;,sans-serif; font-size: 10.5pt;\">The Guide for Applicant and the Model Grant Agreement are available now.</span></p>\r\n<p><span lang=\"EN-US\" style=\"margin: 0px; color: rgb(51, 51, 51); font-family: &quot;Arial&quot;,sans-serif; font-size: 10.5pt;\">The Call texts 2020, the Submission form, Annex 2, 6, 7, 8 have been also updated.</span></p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>"}, {"approvalDate": "May 20, 2020 8:55:42 PM", "lastChangeDate": "May 20, 2020 8:55:42 PM", "content": "<p><span style=\"text-align: left; color: rgb(0, 0, 0); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12px; font-variant: normal; word-spacing: 0px; display: inline; white-space: normal; orphans: 2; float: none; -webkit-text-stroke-width: 0px; background-color: transparent;\">\r\n<p><span lang=\"EN-US\" style=\"margin: 0px; color: rgb(51, 51, 51); font-family: &quot;Arial&quot;,sans-serif; font-size: 10.5pt;\">The Guide for Applicant and the Model Grant Agreement are available now.</span></p>\r\n<p><span lang=\"EN-US\" style=\"margin: 0px; color: rgb(51, 51, 51); font-family: &quot;Arial&quot;,sans-serif; font-size: 10.5pt;\">The Call texts 2020, the Submission form, Annex 2, 6, 7, 8 have been also updated.</span></p>\r\n<p>&nbsp;</p>\r\n</span></p>\r\n<p>&nbsp;</p>"}, {"approvalDate": "Apr 27, 2020 5:04:04 PM", "lastChangeDate": "Apr 27, 2020 5:04:04 PM", "content": "<p><span style=\"background-color: transparent; color: rgb(0, 0, 0); display: inline; float: none; font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\">The Guide for Applicant will be available soon </span><span lang=\"EN-IE\" style=\"background-color: transparent; color: rgb(31, 73, 125); font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 14.66px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\">(expected early May). </span></p>\r\n<p>&nbsp;</p>"}, {"approvalDate": "Mar 24, 2020 12:17:37 PM", "lastChangeDate": "Mar 24, 2020 12:17:37 PM", "content": "<p><span lang=\"EN-IE\" style=\"margin: 0px; font-family: &quot;Arial&quot;,sans-serif; font-size: 10pt;\">The <b>submission deadline</b> has been set to <b>1 December 2020</b>, subject to further extension in case of evolution of the coronavirus crisis.</span></p>\r\n<p><span lang=\"EN-IE\" style=\"margin: 0px; font-family: &quot;Arial&quot;,sans-serif; font-size: 10pt;\"><span style=\"display: inline !important; float: none; background-color: transparent; color: rgb(0, 0, 0); font-family: &quot;Arial&quot;,sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\">The Guide for Applicant and the Model Grant Agreement will be available soon.</span></span></p>\r\n<p><span lang=\"EN-IE\" style=\"margin: 0px; font-family: &quot;Arial&quot;,sans-serif; font-size: 10pt;\"><span style=\"text-align: left; color: rgb(0, 0, 0); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: &quot;Arial&quot;,sans-serif; font-size: 12px; font-variant: normal; word-spacing: 0px; display: inline !important; white-space: normal; orphans: 2; float: none; -webkit-text-stroke-width: 0px; background-color: transparent;\"><span lang=\"EN-IE\" style=\"background-color: transparent; color: rgb(0, 0, 0); font-family: &amp;quot;Arial&amp;quot;,sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\"><span style=\"background-color: transparent; color: rgb(0, 0, 0); display: inline; float: none; font-family: &amp;quot;Arial&amp;quot;,sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\">Missing links have been repaired.</span></span></span></span></p>\r\n<p>&nbsp;</p>"}, {"approvalDate": "Mar 20, 2020 6:23:35 PM", "lastChangeDate": "Mar 20, 2020 6:23:35 PM", "content": "<p><span lang=\"EN-IE\" style=\"margin: 0px; font-family: &quot;Arial&quot;,sans-serif; font-size: 10pt;\">The <b>submission deadline</b> has been set to <b>1 December 2020</b>, subject to further extension in case of evolution of the coronavirus crisis.</span></p>\r\n<p><span lang=\"EN-IE\" style=\"margin: 0px; font-family: &quot;Arial&quot;,sans-serif; font-size: 10pt;\"><span style=\"display: inline !important; float: none; background-color: transparent; color: rgb(0, 0, 0); font-family: &quot;Arial&quot;,sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\">The Guide for Applicant and the Model Grant Agreement will be available soon.</span></span></p>\r\n<p>&nbsp;</p>"}], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3301765": [{"action": "EDIDP-CBRN-MCM-2020 - EDIDP-AG EDIDP Action grant", "plannedOpeningDate": "15 April 2020", "deadlineModel": "single-stage", "deadlineDates": ["01 December 2020"], "budgetYearMap": {"2020": 13500000}, "budgetTopicActionMap": {}}, {"action": "EDIDP-CBRN-DEWS-2020 - EDIDP-AG EDIDP Action grant", "plannedOpeningDate": "15 April 2020", "deadlineModel": "single-stage", "deadlineDates": ["01 December 2020"], "budgetYearMap": {"2020": 13500000}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2020"]}, "description": "<SPAN class=\"topicdescriptionkind\">Specific Challenge</SPAN>:<p><span><span><span style=\"color:black\">The objective of this </span>topic <span style=\"color:black\">is to develop medical counter-measures (MedCM) for EU military forces to face current and emerging CBRN threats (mainly of biological and chemical nature). </span></span></span></p><p><span> </span><span><span><span style=\"color:black\">It thus aims at developing common and shared capabilities for EU military against chemical/biological crisis generated by a natural or provoked event and at treating pathologies or injuries of significant impact. It will thus contribute to respond more efficiently to external conflicts and crises.</span></span></span><span> </span><span> </span></p><p><span>Such medical counter-measures are currently poorly studied by both academia and industry within the EU due to: </span></p><ul level=\"0\"><li><span>their specificity; </span></li><li><span>the large funding to be engaged for R&amp;D; </span></li><li><span>the low occurrence of such threats even though they are proliferating </span><span>worldwide (thus increasing operational risks for military forces); </span></li><li><span>current EU regulations on medicines. </span></li> </ul>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p><span>The proposals must address the development of medical counter-measures (MedCMs) against the chemical, bacteriological and radiological threats listed in the main high-level requirements below. </span></p><p><u><span><span>Targeted activities</span></span></u></p><p><span><span>The proposals must cover the design, prototyping and testing of one or several MedCMs, not excluding upstream or downstream activities. </span></span></p><p><span><span>Compared with the development of a standard medicine these activities must be understood as:</span></span></p><ul level=\"0\"><li><span><span>design: preclinical, <em>in vitro</em> studies;</span></span></li><li><span><span>prototyping: preclinical, <em>in vivo</em> </span></span><span><span>studies <em>(<span><span>The data or information on the kinetics and pharmacodynamics of the product or other relevant data or information, in animals and primates, will allow selection of an effective dose in humans)</span></span></em></span></span>;</li><li><span><span>testing: clinical, phase I </span></span><span><span>studies <em>(<span><span>Phase II and III clinical studies are considered as \u201cqualification\u201d and marketing authorisation is considered as \u201ccertification\u201d)</span></span></em></span></span>.</li> </ul><p><span><span>The targeted activities must in particular include:</span></span></p><ul level=\"0\"><li><span><span>the evaluation of state-of-</span></span><span><span>the-</span></span><span><span>art research in order to identify best MedCM candidates</span></span><span><span>;</span></span></li><li><span><span>the definition of preclinical studies to be performed to develop the best therapeutic or prophylactic candidates; </span></span></li><li><span><span>the realisation of preclinical studies; </span></span></li><li><span><span>the realisation of phase I clinical studies; </span></span></li><li><span><span>the building of relevant documentation for marketing authorization based on the former activities. </span></span></li> </ul><p><u><span><span>Main high-level requirements</span></span></u></p><p><span><span>The proposed MedCMs should fulfil the following requirements:</span></span></p><p><span><span>1. </span></span><u><span><span>General </span></span></u></p><ul level=\"0\"><li><span><span>Efficacy of the MedCMs should be demonstrated on relevant animal models as close as possible as humans during preclinical studies, according to the recommendations of national or European regulatory agencies; </span></span></li><li><span><span>Innocuity should be demonstrated on human volunteers during phase I clinical trials; </span></span></li><li><span><span>The final product is to be administered by medical personnel, at medical treatment facilities. </span></span></li> </ul><p><span><span>2. </span></span><u><span><span>Chemical threat </span></span></u></p><ul level=\"0\"><li><span><span>To develop an efficient MedCM against severe poisoning by any nerve agent or organophosphorus pesticide with, for example, a stoichiometric bioscavenger isolated from human plasma such as human butyrylcholinesterase (BuChE) enzyme from the IV-4 Cohn plasma fraction. </span></span></li> </ul><p><span><span>3. </span></span><u><span><span>Biological threat </span></span></u></p><ul level=\"0\"><li><span><span>To develop an efficient MedCM against toxins poisoning or any B agent for which classical treatments (<em>e.g. </em>antibiotics) are not available with for example immunotherapy. </span></span></li> </ul><p><span><span>4. </span></span><u><span><span>Radiological threat </span></span></u></p><ul level=\"0\"><li><span><span>To develop an efficient radionuclides chelator to treat internal or external radiological contamination of personnel. </span></span></li> </ul>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<ul level=\"0\"><li><span>Provide EU military forces with consistent CBRN medical protections against a large panel of threats; </span></li><li><span>Facilitate the development of CBRN defence capabilities that each Member State or individual government or industry cannot face solely; </span></li><li><span>Develop</span><span> EU autonomous industrial segments. </span></li> </ul>\n", "conditions": "<p><font face=\"Arial, sans-serif\">1.<span style=\"white-space: pre;\">\t</span><strong>List of eligible countries:</strong> Described in section 3 of the call document.</font></p>\n<p><font face=\"Arial, sans-serif\">2.<span style=\"white-space: pre;\">\t</span><strong>Eligibility and admissibility conditions:</strong> Described in section 3 of the call document.</font></p>\n<p>3.<span style=\"white-space: pre;\">\t</span><strong>Evaluation criteria &amp; process:</strong></p>\r\n<p style=\"margin-left: 80px;\"><strong>Operational and financial capacity:</strong> Described in section 3 of the call document.</p>\r\n<p style=\"margin-left: 80px;\"><strong>Exclusion criteria:</strong> Described in section 3 of the call document.</p>\r\n<p style=\"margin-left: 80px;\"><strong>Award criteria, scoring and thresholds: </strong>Described in section 3 of the call document.&nbsp;</p>\r\n<p style=\"margin-left: 80px;\"><strong>Submission and evaluation procedure: </strong>Described in section 3 of the call document.</p>\n<p>&nbsp;4.<span style=\"white-space: pre;\">\t</span><strong>Proposal page limits and layout</strong>: 6<span style=\"margin: 0px; color: black; font-family: &quot;Arial&quot;,sans-serif; font-size: 9pt;\">0 (Part B - Section 6 &amp; 7)&nbsp;</span></p>\r\n<p>&nbsp;</p>\n<p>&nbsp;5.<span style=\"white-space: pre;\">\t</span><strong>Additional requirements</strong></p>\r\n<p style=\"margin-left: 80px;\"><strong>Operational and financial capacity:</strong> Described in section 3 of the call document.</p>\r\n<p style=\"margin-left: 80px;\"><strong>Exclusion criteria:</strong> Described in section 3 of the call document.</p>\n<p>Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.</p>\n<p>&nbsp;6.<span style=\"white-space: pre;\">\t</span><strong>Planning for evaluation and grant agreement:</strong> Described in section 3 of the call document.&nbsp;</p>\n<p>&nbsp;7.&nbsp; &nbsp; &nbsp;<strong>Proposal forms, Model Grant Agreement:</strong></p>\r\n<p style=\"margin-left: 80px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/tpl/pt/pt-edidp_en.docx\" target=\"_blank\">Submission form</a></p>\r\n<p style=\"margin-left: 120px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/tpl/pt/pt-edidp_annex-1_en.xlsx\" target=\"_blank\">Annex 1 &ndash; SMEs and mid-caps participation</a></p>\r\n<p style=\"margin-left: 120px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/tpl/pt/pt-edidp_annex-2_en.xlsx\" target=\"_blank\">Annex 2 &ndash; Budget table &ndash; Actual costs</a></p>\r\n<p style=\"margin-left: 120px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/tpl/pt/pt-edidp_annex-3_en.docx\" target=\"_blank\">Annex 3 &ndash; Declaration of honour</a></p>\r\n<p style=\"margin-left: 120px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/tpl/pt/pt-edidp_annex-4_en.docx\" target=\"_blank\">Annex 4 &ndash; Agreement on pre-existing information (background information)</a></p>\r\n<p style=\"margin-left: 120px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/tpl/pt/pt-edidp_annex-5_en.docx\" target=\"_blank\">Annex 5 &ndash; Statistical information</a></p>\r\n<p style=\"margin-left: 120px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/tpl/pt/pt-edidp_annex-6_en.docx\" style=\"background-color: transparent; color: rgb(0, 102, 204); font-family: Arial,Verdana,sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: underline; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\" target=\"_blank\">Annex 6 &ndash; Declaration of Ownership and Control</a></p>\r\n<p style=\"margin-left: 120px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/tpl/pt/pt-edidp_annex-7_en.docx\" style=\"background-color: transparent; color: rgb(0, 102, 204); font-family: Arial,Verdana,sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: underline; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\" target=\"_blank\">Annex 7 &ndash; Description of operational capacity</a></p>\r\n<p style=\"margin-left: 120px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/tpl/pt/pt-edidp_annex-8_en.xlsx\" style=\"background-color: transparent; color: rgb(0, 102, 204); font-family: Arial,Verdana,sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: underline; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\" target=\"_blank\">Annex 8 &ndash; Mid-cap self-assessment form</a></p>\r\n<p style=\"margin-left: 80px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/mga/edidp-mga_en.docx\" target=\"_blank\">Model Grant Agreement (Multi and Mono</a>)</p>\r\n<p style=\"margin-left: 80px;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/mga/edidp-mga-annex2_en.xlsx\" target=\"_blank\">MGA - Annex 2</a></p>\r\n<p style=\"margin-left: 80px;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/mga/edidp-mga-annex4_en.xlsx\" target=\"_blank\">MGA - Annex 4</a></p>\n<p>8. <span style=\"white-space:pre\">\t</span><strong>Additional documents: To be communicated</strong></p>\r\n<p style=\"margin-left: 80px;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/wp-call/edidp-wp1920_en.pdf \" target=\"_blank\">Work programme 2019-2020</a></p>\r\n<p style=\"margin-left: 80px;\"><font color=\"#000120\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/wp-call/edidp_call-texts-2020_en.pdf\" target=\"_blank\">Call texts 2020</a></font></p>\r\n<p style=\"margin-left: 80px;\"><font color=\"#000120\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/guide/edidp-guide-applicants_en.pdf\" target=\"_blank\">Guide for applicants</a></font></p>\r\n<p style=\"margin-left: 80px;\"><font color=\"#000120\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/edidp/guide/edidp-psi_en.pdf\" target=\"_blank\">Generic Programme Security Instructions</a></font></p>", "supportInfo": "<p>For help related to this call, please contact: <a href=\"mailto:EC-EDIDP-PROPOSALS@ec.europa.eu\" target=\"_blank\">EC-EDIDP-PROPOSALS@ec.europa.eu</a>&nbsp;</p>\r\n<div><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;grantAndTendertype=1;categories=p_registration,pp_roles_and_rights,p_submission_eval;programme=EDIDP;actions=;keyword=;period=2014-2020\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a> &ndash; Proposals submission and evaluation.</div>\r\n<div>&nbsp;</div>\r\n<div><a href=\"http://ec.europa.eu/research/participants/api/contact/index.html\" target=\"_blank\">IT Helpdesk</a> &ndash; Contact the IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.</div>\r\n<div>&nbsp;</div>\r\n<div>&nbsp;</div>\r\n<p>&nbsp;</p>", "sepTemplate": "<p><span style=\"display: inline !important; float: none; background-color: transparent; color: rgb(0, 0, 0); font-family: eui-light,Helvetica Neue,Helvetica,sans-serif; font-size: 12.6px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; line-height: 18.9px; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;\">Please see section 3 of the call document.</span></p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"staticAdditionalInfo": "<p><span><span><span style=\"color:black\">The resilience of the Union and its preparedness to deal with CBRN threats needs to be enhanced, and there are significant cooperation opportunities on CBRN reconnaissance, decontamination, individual and collective protection, as well as on training. A comprehensive set of CBRN capabilities must be capable of providing CBRN scientific and operational assessment and advice to commanders and their staffs during the planning and conduct of operations.</span></span></span></p><p><span><span><span style=\"color:black\">The 2018 Capability Development Plan (CDP) indicates the relevance of deploying dedicated Intelligence, Surveillance, Target Acquisition and Reconnaissance (ISTAR), exploitation and processing capabilities and specialised sensors for detection and early warning of potential CBRN threats to friendly populations and defence forces. Early detection of CBRN threats can be supported by intelligence operations performed through web data mining in dark nets and deep web.</span></span></span></p><p><strong><u><span><span>Proposals are invited against any of the following topics</span></span></u></strong></p><ul level=\"0\"><li><strong><span><span>EDIDP-CBRN-DEWS-2020:</span></span></strong><span><span> Capabilities for CBRN risk assessment, detection, early warning and surveillance;</span></span></li><li><strong><span><span>EDIDP-CBRN-MCM-2020: </span></span></strong><span><span>CBRN medical countermeasures, such as preventive and therapeutic immunotherapy.</span></span></li> </ul>\n<p><span><span>The Union is considering a contribution of up to EUR 13 500 000 to support proposals addressing any of the above-mentioned topics and their associated specific challenge, scope, targeted activities and main high-level requirements.</span></span></p><p><strong><span><span>Several actions, addressing different topics, may be funded under this call.</span></span></strong></p>\n", "latestInfos": [{"approvalDate": "May 29, 2020 1:25:10 PM", "lastChangeDate": "May 29, 2020 1:25:10 PM", "content": "<p><font face=\"Times New Roman\" size=\"3\"><span lang=\"EN-US\" style=\"margin: 0px;\"><font face=\"Calibri\" size=\"3\">The <b>EDIDP 2020 Info Days</b> will take place on <b>22 June.</b>&nbsp;</font></span></font></p>\r\n<p><font face=\"Times New Roman\" size=\"3\"><span lang=\"EN-US\" style=\"margin: 0px;\"><font face=\"Calibri\" size=\"3\">The event is&nbsp;exclusively web streamed and your <b>registration</b> <b>before the 15 June</b> is compulsory on the event webpage <a href=\"https://ec.europa.eu/growth/content/european-defence-industrial-development-programme-information-day-0_en\"><font color=\"#0563c1\">here</font></a>.</font></span></font></p>"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}